Elisabetta Mantengoli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Elisabetta Mantengoli has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Bartoloni
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
3 shared publications - Gian Maria Rossolini
Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, Italy
3 shared publications - Alberto Corrà
Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy, ulssvicenza.it
2 shared publications - Alessia Grassi
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
2 shared publications - Alice Verdelli
Rare Skin Diseases Unit, P.O. Piero Palagi, Azienda USL Toscana Centro, European Reference Network-Skin Member, University of Florence, 50122 Florence, Italy
2 shared publications - Angelo Galano
Microbiology and Virology Unit Careggi University Hospital Florence Italy
2 shared publications
Latest Publications
- Open Access
- 3 February 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (3) , 432-438
The impact of antibiotic therapy in psoriasis patients with active streptococcal infection: A prospective study
The association between psoriasis and streptococcal infection has been widely explored in both children and adults. However, the exact impact of Streptococcus pharyngeal infection on the course of psoriasis is not fully comprehended. This study explored the impact of Streptococcus pharyngeal infection on psoriasis and investigated the effectiveness of systemic antibiotic therapy in conjunction with standard topical treatment for psoriatic patients with concomitant streptococcal throat infection. The research involved 115 patients with mild‐to‐moderate psoriasis, clinically assessed using the Psoriasis Area and Severity Index (PASI). Patients with active streptococcal infection were administered adjunctive systemic antibiotic therapy along with standard local treatment for psoriasis, while psoriasis patients without evidence of infection received the local topical treatment only. Streptococcal infections were more common in psoriasis patients compared to healthy controls. A group of psoriasis patients with active streptococcal throat infections, treated with antibiotics in addition to standard topical psoriasis therapy, did not show any difference in PASI score reduction compared to those without evidence of active infection. While our study did not show a statistically significant reduction in PASI scores in psoriasis patients with streptococcal throat infections treated with antibiotics, it highlights the complex interaction between infection and psoriasis. Larger studies with longer follow‐up may better clarify this relationship, contributing to stronger evidence for or against the use of antibiotics in managing psoriasis triggered by streptococcal infections.
- 3 February 2025
- Published by Wiley in The Journal of Dermatology
- Vol. 52 (3) , 432-438
Open AccessThe impact of antibiotic therapy in psoriasis patients with active streptococcal infection: A prospective study
The association between psoriasis and streptococcal infection has been widely explored in both children and adults. However, the exact impact of Streptococcus pharyngeal infection on the course of psoriasis is not fully comprehended. This study explored the impact of Streptococcus pharyngeal infection on psoriasis and investigated the effectiveness of systemic antibiotic therapy in conjunction with standard topical treatment for psoriatic patients with concomitant streptococcal throat infection. The research involved 115 patients with mild‐to‐moderate psoriasis, clinically assessed using the Psoriasis Area and Severity Index (PASI). Patients with active streptococcal infection were administered adjunctive systemic antibiotic therapy along with standard local treatment for psoriasis, while psoriasis patients without evidence of infection received the local topical treatment only. Streptococcal infections were more common in psoriasis patients compared to healthy controls. A group of psoriasis patients with active streptococcal throat infections, treated with antibiotics in addition to standard topical psoriasis therapy, did not show any difference in PASI score reduction compared to those without evidence of active infection. While our study did not show a statistically significant reduction in PASI scores in psoriasis patients with streptococcal throat infections treated with antibiotics, it highlights the complex interaction between infection and psoriasis. Larger studies with longer follow‐up may better clarify this relationship, contributing to stronger evidence for or against the use of antibiotics in managing psoriasis triggered by streptococcal infections.
- 13 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (6) , 925-932
Skin IL-17A and IFN-γ Production Correlate with Disease Severity in Patients with Psoriasis and Streptococcal Infection
- 13 January 2023
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 143 (6) , 925-932
Skin IL-17A and IFN-γ Production Correlate with Disease Severity in Patients with Psoriasis and Streptococcal Infection